Soleno Therapeutics shares are trading higher after the company announced it received Breakthrough Therapy Designation from the FDA for DCCR extended-release tablets in Prader-Willi Syndrome.
Portfolio Pulse from Benzinga Newsdesk
Soleno Therapeutics' stock is trading higher following the announcement that the FDA granted Breakthrough Therapy Designation for its DCCR extended-release tablets for treating Prader-Willi Syndrome.
April 29, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Soleno Therapeutics' shares are experiencing an uptick after the FDA's Breakthrough Therapy Designation for DCCR tablets aimed at treating Prader-Willi Syndrome.
The FDA's Breakthrough Therapy Designation is a significant regulatory milestone that can expedite the development and review process for promising new medicines. This designation for Soleno Therapeutics' DCCR tablets directly impacts the company's valuation and investor perception, likely leading to a short-term increase in stock price due to heightened investor interest and optimism about the drug's market potential.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100